Madrigal Wins EU Approval For REZDIFFRA In MASH With Liver Fibrosis
Madrigal Pharmaceuticals announced that the European Commission (EC) has granted conditional marketing authorization for REZDIFFRA, the first and only approved therapy in the European Union (EU) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. The approval follows a positive CHMP opinion in June 2025 and is valid across all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway.
“This approval of REZDIFFRA marks a historic breakthrough for patients in Europe living with MASH, a serious and progressive live...